Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns

The findings of this study provide relevant insights into tailoring b/tsDMARD therapy to maximize clinical benefit and potentially identify patients with the greatest unmet need.

Authors

Chao Lu (ORCID: https://orcid.org/0000-0003-4650-459X)
Jessica A. Walsh (ORCID: https://orcid.org/0000-0002-4563-0845)
Sarah Welby (ORCID: https://orcid.org/0000-0003-3217-9490)
Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
Olga Pilipczuk (ORCID: https://orcid.org/0000-0001-7078-2544)
Jie Song (ORCID: https://orcid.org/0000-0002-7357-2136)
H. Roqué

Institutions

VA Salt Lake City Healthcare System (US)
Utah Department of Health (US)
UCB Pharma (Belgium) (BE)
The University of Texas Southwestern Medical Center (US)

Publication Details

Journal: Journal of Managed Care & Specialty Pharmacy
Published: 2025-07-24
DOI: https://doi.org/10.18553/jmcp.2025.31.8.808
Primary Topic: Spondyloarthritis Studies and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns

Authors

Institutions

Publication Details

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.